EUROFINS SCIENT Debt/Equity Ratio 2018-2024 | ERFSF

EUROFINS SCIENT debt/equity ratio for the quarter ending June 30, 2024 was 0.64.

  • EUROFINS SCIENT average debt/equity ratio for 2023 was 0.62, a 3.13% increase from 2022.
  • EUROFINS SCIENT average debt/equity ratio for 2022 was 0.64, a 12.28% decline from 2021.
  • EUROFINS SCIENT average debt/equity ratio for 2021 was 0.57, a 29.63% increase from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

EUROFINS SCIENT Debt/Equity Ratio 2018-2024 | ERFSF

  • EUROFINS SCIENT average debt/equity ratio for 2023 was 0.62, a 3.13% increase from 2022.
  • EUROFINS SCIENT average debt/equity ratio for 2022 was 0.64, a 12.28% decline from 2021.
  • EUROFINS SCIENT average debt/equity ratio for 2021 was 0.57, a 29.63% increase from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$88.4B
Cencora (COR)$45.7B
Natera (NTRA)$23.1B
DiDi Global (DIDIY)$22B
ICON (ICLR)$18B
Avantor (AVTR)$14.7B
Viatris (VTRS)$13.9B
Revvity (RVTY)$13.9B
BioMerieux (BMXMF)$12.6B
CochLear (CHEOY)$12.1B
Solventum (SOLV)$11.6B
Medpace Holdings (MEDP)$10.9B
Doximity (DOCS)$9.7B
Charles River Laboratories (CRL)$9.5B
HealthEquity (HQY)$8.7B
Sonic Healthcare (SKHHY)$8.2B
Bausch + Lomb (BLCO)$6.3B
Amplifon S.p.A (AMFPF)$5.9B
Organon (OGN)$4.1B
Sotera Health (SHC)$3.7B
BrightSpring Health Services (BTSG)$3B
Surgery Partners (SGRY)$2.6B
Concentras Parent (CON)$2.5B
GeneDx Holdings (WGS)$2.5B
Alignment Healthcare (ALHC)$2.3B
Ardent Health Partners (ARDT)$2.3B
Premier (PINC)$2B
PACS (PACS)$2B
GoodRx Holdings (GDRX)$1.7B
Teladoc Health (TDOC)$1.7B